<>
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as a critical public health crisis in urban India.
In Plain English: The Clinical Takeaway
- The Silent Progression: Metabolic syndrome—a cluster of conditions including high blood pressure, high blood sugar, and excess body fat—causes fat to accumulate in the liver, often without early symptoms.
- Beyond Alcohol: This disease occurs in individuals with little to no alcohol consumption, meaning it is fundamentally driven by systemic metabolic health rather than toxin exposure.
The Pathophysiological Mechanism: Why the Liver Fails
Dr. Jitendra Singh, Union Minister of State, recently emphasized the necessity of a "Mission-Mode" response to tackle the dual burden of liver disease and Type-2 diabetes.
Bridging Global Standards and Local Infrastructure
A significant advancement is the establishment of a Good Manufacturing Practice (GMP) facility for cellular therapy at the Institute of Liver and Biliary Sciences (ILBS). This facility represents a shift from purely symptomatic management to regenerative medicine, potentially offering new avenues for patients with end-stage liver failure.
Contraindications & When to Consult a Doctor
Conclusion
References
- Eslam, M., et al. (2020).
- World Health Organization Global Report on Non-Communicable Diseases (2025 update).
- Centers for Disease Control and Prevention: Epidemiological Trends in Metabolic Syndrome.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
